2004
DOI: 10.1783/1471189041261429
|View full text |Cite
|
Sign up to set email alerts
|

FFPRHC Guidance (July 2004): Contraceptive choices for breastfeeding women

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
3
2
2

Relationship

0
7

Authors

Journals

citations
Cited by 53 publications
(3 citation statements)
references
References 36 publications
0
3
0
Order By: Relevance
“…In choosing contraceptive methods other than LAM, the non-hormonal methods of contraception such as reversible barrier methods or the copper intrauterine device (IUD), or permanent surgical methods, are usually preferred for breastfeeding mothers. This is because they avoid transfer of hormones into milk which poses a theoretical risk to the infant [9] [10].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…In choosing contraceptive methods other than LAM, the non-hormonal methods of contraception such as reversible barrier methods or the copper intrauterine device (IUD), or permanent surgical methods, are usually preferred for breastfeeding mothers. This is because they avoid transfer of hormones into milk which poses a theoretical risk to the infant [9] [10].…”
Section: Introductionmentioning
confidence: 99%
“…A single study of a desogestrel pill, however reported two cases of gynecomastia in exposed infants [11]. Overall, systematic reviews investigating the effects of hormonal contraception (COC, POPs and injectables) on breast milk concluded that there is insufficient evidence to establish if hormonal contraception indeed has any effect on breast milk quantity or quality, and provide some reassurance that hormonal contraception does not have an adverse effect on infant growth or development [10].…”
Section: Introductionmentioning
confidence: 99%
“…Placement of the etonogestrel contraceptive implant in the early postpartum period (1–3 days) has been shown to be noninferior to standard insertion time (4–8 weeks) for time to lactogenesis stage II, breastfeeding rates and infant growth [ 7 ]. Depot medroxyprogesterone acetate (DMPA) can be given as an intramuscular injection and does not adversely affect milk supply or infant growth and development [ 4 , 15 17 ]. There are conflicting clinical recommendations on early postpartum initiation of DMPA and breastfeeding outcomes, however a systematic review concluded that current evidence is too methodologically weak to show this [ 18 ].…”
Section: Introductionmentioning
confidence: 99%